Literature DB >> 2737760

In-vitro activity of lomefloxacin (SC-47111) and other quinolones.

Z M Sun1, J P Maskell, S C Sehgal, J D Williams.   

Abstract

The in vitro activity of lomefloxacin, a new difluorinated quinolone, was compared to that of ciprofloxacin, ofloxacin, norfloxacin and other relevant antibacterial agents. Lomefloxacin and norfloxacin shared similar activity, whereas ofloxacin and in particular ciprofloxacin showed superior activity. Most gram-negative aerobes were susceptible to all four quinolones, 90% of isolates were inhibited by 1 mg/l. The gram-positive organisms were generally less susceptible, although 90% of Staphylococcus aureus isolates were inhibited by 0.5 mg/l of ciprofloxacin and ofloxacin; values for lomefloxacin and norfloxacin were 1 mg/l and 2 mg/l, respectively; susceptibility was not affected by methicillin resistance. Neisseria gonorrhoeae and Haemophilus influenzae were highly susceptible to the quinolones, especially ciprofloxacin. Penicillin/ampicillin-resistant isolates remained susceptible to the quinolones.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737760     DOI: 10.1007/bf01644019

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  7 in total

1.  In vitro activity of the new 4-quinolone compound Ro 23-6240.

Authors:  A M Clarke; S J Zemcov
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

2.  Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.

Authors:  L J Piddock; J M Diver; R Wise
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

3.  The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

Authors:  A King; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

4.  Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

Authors:  H H Gadebusch; D L Shungu; E Weinberg; S K Chung
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

5.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  In-vitro selection of bacteria resistant to the 4-quinolone agents.

Authors:  D I Limb; D J Dabbs; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

7.  The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.

Authors:  A King; K Shannon; J Slegg; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-08       Impact factor: 5.790

  7 in total
  1 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.